Linatrio Tablets

Composition

• Linagliptin – 5 mg
• Dapagliflozin – 10 mg
• Metformin Hydrochloride (Sustained Release) – 500 mg

---

Mechanism of Action

Linagliptin inhibits the DPP-4 enzyme, increasing incretin hormone levels (GLP-1 and GIP). This enhances insulin secretion and reduces glucagon levels in a glucose-dependent manner.

Dapagliflozin works by inhibiting the SGLT2 transporter in the kidneys, promoting urinary glucose excretion and thereby lowering blood glucose levels independently of insulin.

Metformin Hydrochloride (SR) reduces hepatic glucose production, improves insulin sensitivity, and enhances peripheral glucose uptake. The sustained-release formulation ensures gradual drug release for prolonged glycemic control with better gastrointestinal tolerability.

---

Key Benefits

• Triple-action mechanism for superior glycemic control
• Reduces fasting and postprandial blood glucose levels
• Promotes glucose excretion through urine
• Improves insulin secretion and sensitivity
• Helps reduce HbA1c levels
• Sustained-release formulation for prolonged effect

---

Indications

• Type 2 Diabetes Mellitus
• Patients inadequately controlled on dual therapy
• Advanced combination therapy for improved glycemic management

---

Dosage & Administration

• To be taken as directed by the physician
• Usually taken once daily with meals
• Tablets should be swallowed whole and not crushed or chewed

---

Precautions

• Monitor renal function before and during treatment
• Risk of dehydration due to increased urinary glucose excretion
• Maintain adequate hydration
• Use cautiously in elderly patients
• Regular monitoring of blood glucose is recommended

---

Contraindications

• Type 1 Diabetes Mellitus
• Diabetic ketoacidosis
• Severe renal impairment
• Known hypersensitivity to any component

---

Storage

• Store in a cool and dry place below 25°C
• Protect from light and moisture
• Keep out of reach of children

---

Packaging

• 10 x 10 Tablets